Jardix 10 Tablet contains Empagliflozin 10 mg, a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the management of type 2 diabetes mellitus. Empagliflozin acts by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion, thereby lowering plasma glucose levels. Jardix 10 is prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Clinical studies have demonstrated its efficacy in reducing HbA1c levels, fasting plasma glucose, and body weight, with additional cardiovascular benefits in patients with established cardiovascular disease. The recommended dose is typically 10 mg once daily, with or without food, and may be adjusted based on therapeutic response and tolerability. Common adverse effects include urinary tract infections, genital mycotic infections, increased urination, and dehydration. Caution is advised in patients with renal impairment, hypotension, or risk of ketoacidosis. Jardix 10 should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of renal function, blood glucose, and hydration status is recommended during therapy. Jardix 10 offers a valuable option for improving glycemic control and reducing cardiovascular risk in type 2 diabetes management.